Chimerix Inc.

0.9506+0.0005+0.05%Vol 116.35K1Y Perf -56.81%
Nov 29th, 2023 16:00 DELAYED
BID0.9500 ASK0.9700
Open0.9678 Previous Close0.9501
Pre-Market- After-Market1.01
 - -  0.06 6.25%
Target Price
8.00 
Analyst Rating
Strong Buy 1.00
Potential %
741.57 
Finscreener Ranking
★★★★★     68.03
Insiders Trans % 3/6/12 mo.
100/67/43 
Value Ranking
★★★★★     75.83
Insiders Value % 3/6/12 mo.
100/70/39 
Growth Ranking
★★★★★     79.29
Insiders Shares Cnt. % 3/6/12 mo.
100/89/75 
Income Ranking
 —    -
Price Range Ratio 52W %
4.66 
Earnings Rating
Sell
Market Cap84.50M 
Earnings Date
2nd Nov 2023
Alpha-0.01 Standard Deviation0.23
Beta1.13 

Today's Price Range

0.95000.9700

52W Range

0.88002.40

5 Year PE Ratio Range

-6.60-2.80

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.05%
1 Month
-0.67%
3 Months
-14.36%
6 Months
-31.12%
1 Year
-56.81%
3 Years
-74.79%
5 Years
-71.11%
10 Years
-94.07%

TickerPriceChg.Chg.%
CMRX0.95060.00050.05
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
16.10
16.40
0.01
0.01
9.67K
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
98.70
-230.20
-229.90
-18 023.40
-
RevenueValueIndustryS&P 500US Markets
33.01M
0.37
-48.37
-18.68
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.22-0.27-22.73
Q02 2023-0.23-0.218.70
Q01 2023-0.24-0.240.00
Q04 2022-0.24-0.240.00
Q03 20222.102.7530.95
Q02 2022-0.24-0.27-12.50
Q01 2022-0.35-0.2820.00
Q04 2021-0.11-0.45-309.09
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.230.00-
12/2023 QR-0.234.17Positive
12/2023 FY-0.95-5.56Negative
12/2024 FY-0.80-3.90Negative
Next Report Date-
Estimated EPS Next Report-0.22
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume116.35K
Shares Outstanding88.89K
Shares Float80.00M
Trades Count971
Dollar Volume110.98K
Avg. Volume343.66K
Avg. Weekly Volume152.58K
Avg. Monthly Volume409.59K
Avg. Quarterly Volume468.81K

Chimerix Inc. (NASDAQ: CMRX) stock closed at 0.9506 per share at the end of the most recent trading day (a 0.05% change compared to the prior day closing price) with a volume of 116.35K shares and market capitalization of 84.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Chimerix Inc. CEO is Michael Sherman.

The one-year performance of Chimerix Inc. stock is -56.81%, while year-to-date (YTD) performance is -48.89%. CMRX stock has a five-year performance of -71.11%. Its 52-week range is between 0.88 and 2.395, which gives CMRX stock a 52-week price range ratio of 4.66%

Chimerix Inc. currently has a PE ratio of 1.10, a price-to-book (PB) ratio of 0.60, a price-to-sale (PS) ratio of 5.04, a price to cashflow ratio of -, a PEG ratio of -, a ROA of 75.51%, a ROC of 80.10% and a ROE of 84.75%. The company’s profit margin is -%, its EBITDA margin is -229.90%, and its revenue ttm is $33.01 Million , which makes it $0.37 revenue per share.

Of the last four earnings reports from Chimerix Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. Chimerix Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Chimerix Inc. is Strong Buy (1), with a target price of $8, which is +741.57% compared to the current price. The earnings rating for Chimerix Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Chimerix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Chimerix Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.45, ATR14 : 0.06, CCI20 : -50.76, Chaikin Money Flow : -0.14, MACD : -0.01, Money Flow Index : 31.03, ROC : -3.46, RSI : 46.51, STOCH (14,3) : 36.89, STOCH RSI : 0.00, UO : 35.91, Williams %R : -63.11), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Chimerix Inc. in the last 12-months were: Andriole Michael (Buy at a value of $58 938), David Jakeman (Sold 6 840 shares of value $9 260 ), Demski Martha (Buy at a value of $19 980), Fred A. Middleton (Buy at a value of $24 152), Middleton Fred (Buy at a value of $62 892)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Chimerix Inc.

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes a treatment for acute myeloid leukemia (or AML) and an antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment--pharmaceuticals.

CEO: Michael Sherman

Telephone: +1 919 806-1074

Address: 2505 Meridian Parkway, Durham 27713, NC, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

54%46%

 

News

Stocktwits